Reducing pain and discomfort during and after bone marrow aspiration

Reducing pain and discomfort during and after bone marrow aspiration - REPADI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON42943

Enrollment

Registered

2016-10-12

Start date

2016-12-14

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pijn en angstbeleving Bone marrow aspiration and biopsy bone marrow biopsy

Interventions

Intervention treatment: Midazolam 7,5mg, oral, single dose + morphine 10mg, oral, single dose - Midazolam is a benzodiazepine with anxiolytic, sedative and possible muscle relaxant and anti-convulsiv

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients with an indication to undergo a first bone marrow aspiration in MC Slotervaart. 2. Age > 18 years 3. Patient is capable to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Known allergy for any of the study medicines 2. Pregnancy 3. In hospital patients

Design outcomes

Primary

Measure	Time frame
Main study parameters - Visual Analogue Scale (VAS) for pain, directly after the procedure - Visual Analogue Scale (VAS) for anxiety, fear for a next BMAB two weeks after procedure	—

Secondary

Measure	Time frame
Secondary study parameters/endpoints - Fear of Pain Questionnaire-III - VAS for pain and anxiety at other moments than described at the main study parameters - 5 point Likert scale, fear for a BMAB - VAS for discomfort - Possibility to follow instructions during the procedure	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)